78442-20-3

Upstream product

• 69384-05-0 3-(3-aminopropoxy)-N,N-dimethylbenzenemethanamine 
• 78441-23-3 3,4-dimethoxy-1,2,5-thiadiazole-1-oxide 

Relevant academic research and scientific papers

HISTAMINE H2-ANTAGONISTS

Histamine H 2-antagonists of the formula STR1 wherein p is 1 or 2; R 1 is hydroxy, amino, substituted amino or a 5-to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

THIADIAZOLE HISTAMINE H2-ANTAGONISTS

Histamine H 2-antagonists of the formula STR1 wherein p is 1 or 2; R 1 is hydroxy, amino, substituted amino or a 5-to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

CHEMICAL COMPOUNDS

Histamine H 2-antagonists of the formula STR1 wherein p is 1 or 2; R 1 is hydroxy, amino, substituted amino or a 5-to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.